1237117-14-4 Usage
Description
2-Chloro-4-(2-chlorophenyl)benzoic acid is an organic compound characterized by its chlorinated aromatic structure. It is a derivative of benzoic acid with two chlorine atoms attached to specific positions on the benzene ring, which may confer unique chemical and biological properties.
Uses
Used in Pharmaceutical Industry:
2-Chloro-4-(2-chlorophenyl)benzoic acid is used as an active pharmaceutical ingredient for the treatment of endometrial cancer and endometriosis. Its chemical structure may allow it to interact with specific biological targets, such as receptors or enzymes, that are involved in the development and progression of these conditions.
Used in Cancer Treatment:
2-Chloro-4-(2-chlorophenyl)benzoic acid is utilized as a therapeutic agent for endometrial cancer, a type of cancer that originates in the endometrium, the inner lining of the uterus. Its potential mechanism of action may involve targeting specific molecular pathways or processes that contribute to cancer cell growth and survival.
Used in Endometriosis Treatment:
In addition to cancer treatment, 2-Chloro-4-(2-chlorophenyl)benzoic acid is also used for the treatment of endometriosis, a medical condition where tissue similar to the endometrium grows outside the uterus, causing pain and other complications. The compound may help alleviate symptoms and address the underlying causes of the disease by modulating relevant biological processes.
Check Digit Verification of cas no
The CAS Registry Mumber 1237117-14-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,7,1,1 and 7 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1237117-14:
(9*1)+(8*2)+(7*3)+(6*7)+(5*1)+(4*1)+(3*7)+(2*1)+(1*4)=124
124 % 10 = 4
So 1237117-14-4 is a valid CAS Registry Number.
1237117-14-4Relevant articles and documents
CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 48-49, (2010/02/07)
The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceut
